Press Releases
Calgary, Alberta--(Newsfile Corp. - May 23, 2024) - Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) ("Greenfire" or the "Company"), a Calgary-based energy company focused on the sustainable production and development of thermal energy resources from the Athabasca region of Alberta, Canada, is pleased to announce that Greenfire will give a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place... (continue reading...)
Local 533 Members Win Significant Pay Increases, Improved Benefits
RENO, Nev., May 23, 2024 /PRNewswire/ -- Members of Teamsters Local 533 have overwhelmingly ratified a new five-year collective bargaining agreement with Waste Management. The contract covers over 250 workers who service the communities of Lyon, Storey, and Washoe counties.
"I want to... (continue reading...)
-Oral presentation on June 1, 2024-
TARRYTOWN, N.Y., May 23, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced that clinical and biomarker data from its ST101 Phase 2 study in GBM will be delivered during an oral presentation on June 1, 2024 at the upcoming 2024 American Society of... (continue reading...)
nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model
Data support further clinical exploration of nab-sirolimus as a single agent or in combination
LOS ANGELES, May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and... (continue reading...)
- ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels
- ELI-002 7P generated an mKRAS-specific T cell response in 100% of patients including responses targeting all mKRAS mutations enrolled (G12D, V, R and G13D)
- mKRAS-specific T cells were polyfunctional with 66.7% (4/6) of evaluable patients having both CD8+ and CD4+ responses at the 4.9 mg Phase 2 dose level
- Tumor... (continue reading...)
More Press Releases
View Older Stories-
Power Integrations to Present at Upcoming Investor Conferences
-
Premier Health Reports 2024 Second Quarter Results
-
Titanium Transportation Group Declares Quarterly Dividend
-
ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.
-
Community Bancorp. Re-Elects Directors and Discusses Strong 2023 and First Quarter 2024 Results at Annual Shareholders' Meeting
-
EDETEK Launches Continuous Study Monitoring Module for CONFORM™ Informatics
-
CXApp Inc. (Nasdaq: CXAI) Announces Record NRR Growth for Q1’24 & Launch of CXAI VU in collaboration with Google Cloud
-
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
-
MTTR Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Matterport to CoStar Group
-
SSR Mining Announces Voting Results From 2024 Annual and Special Meeting of Shareholders
-
Tiny Announces Annual General and Special Meeting of Shareholders
-
Pan American Silver Releases 2023 Sustainability Report
-
HRBR Stockholders: Robbins LLP Reminds HRBR Stockholders of Securities Fraud Class Action Against Harbor Diversified, Inc.
-
DOCS INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS
-
Trailblazing Dragons' Den Star Named United Nations Association in Canada's 2024 Global Citizen Laureate
-
INTC Stockholders: Robbins LLP Reminds INTC Stockholders of Securities Fraud Class Action Against Intel Corporation
-
Graphic Packaging Holding Company Declares Quarterly Dividend
-
Crypto Specialist Bitwise’s First-Ever Spot Ethereum ETF Receives Key SEC Approval
-
Sailfish Reports Q1 2024 Results
-
Gesa Credit Union Announces Agreement to Acquire Security State Bank
-
EDETEK to Showcase "End-to-End Digital Data Pipeline for Clinical Trials" at AWS Healthcare and Life Sciences Meetup in Los Angeles, CA
-
Pei enters the MSCI COLCAP index
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
-
NextEra Energy board declares quarterly dividend
-
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers
-
American Aires Extends Global Expansion by Opening Latest International Fulfillment Center in the UK
-
Deveron Announces Dates for Q3 2024 Earnings Release
-
Aurania Announces Closing of Tranche 2 of Private Placement
-
Avenix Fzco Introduces New Expert Advisor Pivozon for Enhanced Forex Trading on EURUSD
-
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
-
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2024 Annual Meeting
-
PARAMOUNT GLOBAL AND CHARTER COMMUNICATIONS ANNOUNCE NEW MULTI-YEAR AGREEMENT FOR DISTRIBUTION OF PARAMOUNT'S LINEAR NETWORKS, CBS OWNED-AND-OPERATED STATIONS AND DIRECT-TO-CONSUMER STREAMING SERVICES
-
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
-
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SILVERCORP REPORTS ADJUSTED NET INCOME OF $39.3 MILLION, $0.22 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $91.6 MILLION FOR FISCAL 2024
-
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
-
Special Olympics Florida and Orlando Health Announce Five-Year Partnership
-
Extraordinary 80+ Acre Paradise Island, Boca Grande, FL, Hits Market After 70-Years: A Once-in-a-Lifetime Opportunity for Discerning Buyers
-
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
-
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
-
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results
-
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
-
KinderCare Learning Companies Applauds Bipartisan Effort to Support Working Families through Child Care Access
-
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
-
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
-
EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
-
Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
-
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m